

North Shore Pediatric Therapy in Chicago Joins BlinkLab's US Registrational Study

- **US-based North Shore Pediatric Therapy ("NSPT") is the second clinical site to join BlinkLab's registrational study.**
- **Located in the Chicago area, NSPT is a recognized leader in early autism intervention services, specializing in Applied Behavior Analysis (ABA), neuropsychology, speech therapy, occupational therapy, and mental health support.**
- **The NSPT clinical trial site is set to begin patient recruitment and diagnostic testing in the coming weeks, supporting timely and efficient data collection for the study.**
- **Together, with PriMED Clinical Research, these two leading US-based autism centers provide access to a large pool of diverse subjects that will accelerate the recruitment process and ensure high-quality data collection.**

BlinkLab Limited (ASX:BB1) ("BlinkLab", or the "Company"), an innovative digital healthcare company developing AI-powered smartphone technology to transform the autism and ADHD diagnostic markets, is pleased to announce that **North Shore Pediatric Therapy ("NSPT")** is joining our US clinical study. NSPT is the second US-based site to on-board for the 100-patient initial phase of the registrational study. Enrolment from the NSPT-site is expected to commence in the coming weeks.

NSPT was selected for this study due to its extensive expertise in administering the ADOS-2 diagnostic tool, which is widely recognized as the gold standard for autism diagnosis. Their experienced neuropsychology team specializes in conducting comprehensive, play-based assessments that evaluate social, emotional, and communication behaviors, ensuring precise and reliable autism diagnoses. As part of our US registrational study, NSPT's use of the ADOS-2 will serve as a critical benchmark for standard-of-care comparisons, helping validate the effectiveness of our Blinklab Dx 1 test.

In addition to their clinical expertise, NSPT provides access to a diverse population of children throughout the Chicago area, which is an essential factor in ensuring the study reflects a broad range of backgrounds and developmental profiles. Their ability to recruit children as young as 18 months old is particularly valuable for the BlinkLab study, as our mission is to enable early diagnosis and improve long-term outcomes for children with autism. With a strong track record in early intervention and autism diagnostics, NSPT's participation enhances the study's robustness, credibility, and real-world applicability, ultimately contributing to the advancement of Blinklab's more accurate and accessible autism screening tool.

About North Shore Paediatric Therapy

North Shore Pediatric Therapy (NSPT) is a leading provider of comprehensive pediatric services in the Chicago area, specializing in the evaluation and treatment of autism. With over two decades of experience, NSPT offers a multidisciplinary approach that includes Applied Behavior Analysis (ABA) therapy, speech therapy, occupational therapy, physical therapy, mental health services, and neuropsychological diagnostics.

Each year, NSPT conducts neuropsychological evaluations for over 800 children, assisting in the diagnosis of various developmental and behavioral conditions, including autism. The neuropsychology team administers the ADOS-2, a gold standard assessment that evaluates how a child interacts with their environment. The ADOS-2 is a play-based diagnostic tool that probes for social and emotional behaviors, providing the most accurate and research-backed method for diagnosing or excluding autism. Through this advanced methodology, NSPT ensures that every child receives a comprehensive and precise evaluation, allowing families to access the appropriate interventions and support.

NSPT is at the forefront of scientific innovation, integrating the latest evidence-based practices and therapeutic techniques to deliver cutting-edge, high-quality care. Their team includes leading neuropsychologists with expertise in pediatric assessments, ensuring that children benefit from the most thorough and individualized evaluations available. By combining advanced diagnostic tools with a compassionate, family-centered approach, NSPT remains dedicated to helping children with autism and other developmental challenges reach their full potential while supporting families through every step of the journey.

This announcement has been approved by the Board of Directors

For further information please contact:

Dr. Henk-Jan Boele
Chief Executive Officer
henkjan@blinklab.org
M: +31 (0) 611 132 247

Brian Leedman
Non-Executive Chairman
brian@blinklab.org
M: +61 (0) 412 281 780



About BlinkLab Limited

BlinkLab, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. Our most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention. BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge most advanced technological innovations with groundbreaking scientific research.